🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanghai Pharmaceuticals Holding clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Shanghai Pharmaceuticals Holding as lead sponsor. Synced 27 Sep 2026
14Current trials
13Recruiting now
6Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanghai Pharmaceuticals Holding is the lead sponsor of 14 current clinical trials in our China register. 13 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are SPH4336, LT3001 Drug and SPH5030. The most-studied condition is Advanced Solid Tumors.

ClinicalTrials.gov trials by status

  • Recruiting1393%
  • Not yet open17%

Trials by phase

  • Phase 2429%
  • Phase 1/2321%
  • Phase EARLY_PHASE1321%
  • Phase 2/3214%
  • Phase 1214%
01

Clinical trials sponsored by Shanghai Pharmaceuticals Holding

14 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
NCT05944224 · Advanced Solid Tumors
Phase 1/2 Recruiting 2023-10 China
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
NCT05686642 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Phase 2 Recruiting 2023-04 China
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
NCT05872347 · ClinicalTrials.gov ↗ · Breast Cancer Brain Metastases
Drug: SPH4336
Phase 2 Recruiting 2023-09 China
Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer
NCT05744687 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Breast Cancer
Drug: SPH4336
Phase 2/3 Recruiting 2023-04 China
A Clinical Study of SPH7854 Granules in Healthy Subjects.
NCT06483373 · ClinicalTrials.gov ↗ · Inflammatory Bowel Disease
Phase EARLY_PHASE1 Recruiting 2024-05 China
SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors
NCT05245058 · ClinicalTrials.gov ↗ · HER2-positive Advanced Solid Tumors
Drug: SPH5030
Phase EARLY_PHASE1 Recruiting 2022-01 China
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
NCT05145361 · ClinicalTrials.gov ↗ · NMO Spectrum Disorder
Drug: B001
Phase EARLY_PHASE1 Recruiting 2022-04 China
A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors
NCT06214143 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: T3011
Phase 1/2 Recruiting 2024-01 China
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
NCT06434597 · ClinicalTrials.gov ↗ · Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
Drug: SPH5030
Phase 2 Recruiting 2024-07 China
A Clinical Study of T3011 in Subjects With Advanced Melanoma
NCT06214156 · ClinicalTrials.gov ↗ · Advanced Melanoma
Drug: T3011
Phase 1/2 Recruiting 2024-01 China
A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.
NCT06839131 · ClinicalTrials.gov ↗ · Healthy Participants
Phase 1 Recruiting 2025-03 China
A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.
NCT06487455 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
Phase 1 Recruiting 2024-08 China
Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05860465 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Breast Cancer
Drug: SPH4336
Phase 2/3 Recruiting 2023-09 China
A Phase II Clinical Study of LT3001 for Injection in the Treatment of Acute Ischemic Stroke
NCT07754825 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke
Phase 2 Not yet open 2026-09 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai Pharmaceuticals Holding trials

6 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai Pharmaceuticals Holding trials

11 conditions
Advanced Solid Tumors2Acute Ischemic Stroke2Locally Advanced or Metastatic Breast Cancer2Breast Cancer Brain Metastases1Inflammatory Bowel Disease1HER2-positive Advanced Solid Tumors1NMO Spectrum Disorder1Biliary Tract or Colorectal Cancer With Her2-positive/Mutated1Advanced Melanoma1Healthy Participants1Advanced Solid Tumor1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1413

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Tumors

SponsorTrials
Sichuan Kelun-Biotech Biopharmaceutical9
Jiangsu HengRui Medicine7
Suzhou Suncadia Biopharmaceuticals7
Shanghai Hengrui Pharmaceutical6
MediLink Therapeutics (Suzhou)5
Hangzhou Zhongmei Huadong Pharmaceutical5
Hansoh BioMedical R&D Company4
Akeso4
Vividion Therapeutics3
Multitude Therapeutics3

Sponsors with the most current trials registered for this condition.

06

Questions about Shanghai Pharmaceuticals Holding trials

How many clinical trials does Shanghai Pharmaceuticals Holding sponsor?

Shanghai Pharmaceuticals Holding is the lead sponsor of 14 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Pharmaceuticals Holding trials recruiting?

Yes. 13 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Pharmaceuticals Holding testing?

Its current trials name 6 drugs and biologicals as interventions. The most frequent are SPH4336 (4), LT3001 Drug (2), SPH5030 (2), T3011 (2) and B001 (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 27 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.